Table S1 Demographics and clinical characteristics of patients with COVID-19 (n=66)

| Characteristics                          |      |
|------------------------------------------|------|
| Age, mean (SD)                           | 47.09 (13.61) |
| Sex                                      |      |
| Men                                      | 33 (50) |
| Women                                    | 33 (50) |
| Disease severity status                  |      |
| Mild/general                             | 47 (82.46) |
| Severe/critical                          | 19 (33.33) |
| Comorbidities                            |      |
| Hypertension                             | 11 (19.30) |
| Diabetes                                 | 9 (15.79) |
| Cardiovascular diseases                  | 2 (3.51) |
| Chronic obstructive pulmonary disorder   | 2 (3.51) |
| Chronic liver diseases                   | 11 (19.30) |
| Others                                   | 5 (8.77) |
| Signs and symptoms                       |      |
| Fatigue                                  | 17 (31.48) |
| Fever                                    | 37 (68.52) |
| Cough                                    | 20 (37.04) |
| Sputum                                   | 16 (29.63) |
| Dyspnea                                  | 4 (7.41) |
| Therapy                                  |      |
| Hormone                                  | 9 (16.07) |
| Antiviral drugs                          | 47 (83.93) |
| Interferon                               | 49 (87.50) |
| Chinese herbs                            | 35 (62.50) |

SD: standard deviation. Number (percentage). /number: the number of patients who reported this part of the data.
Table S2 Univariate logistic regression analysis for the influencing factors of SARS-CoV2 viral-specific IgG antibody in patients with COVID-19 after one year of recovery

| Factors                  | OR   | 95%CI      | P     |
|--------------------------|------|------------|-------|
| Sex                      | 0.64 | 0.15-2.78  | 0.552 |
| Age                      | 0.98 | 0.93-1.04  | 0.512 |
| Onset days               | 0.90 | 0.75-1.07  | 0.240 |
| Virus negative days      | 1.01 | 0.91-1.11  | 0.913 |
| Hospital days            | 1.02 | 0.95-1.10  | 0.543 |
| Status                   | 0.39 | 0.04-3.55  | 0.402 |
| Comorbidities            | 0.43 | 0.08-2.37  | 0.332 |
| Antiviral therapy        | 1.71 | 0.18-16.40 | 0.640 |
| Chinese herbs            | 1.24 | 0.26-5.83  | 0.787 |
| Lymphocyte_H             | 1.21 | 0.25-5.94  | 0.811 |
| Neutrophil_H             | 1.21 | 0.92-1.58  | 0.170 |
| NLR_H                    | 1.07 | 0.95-1.20  | 0.258 |
| Hemoglobin_H             | 0.99 | 0.94-1.04  | 0.665 |
| Platelet_H               | 1.01 | 1.00-1.02  | 0.193 |
| PLR_H                    | 1.00 | 1.00-1.01  | 0.356 |
| CRP_H                    | 1.01 | 0.97-1.04  | 0.680 |
| CD3_H                    | 1.00 | 0.99-1.00  | 0.549 |
| CD4_H                    | 1.00 | 0.99-1.00  | 0.905 |
| CD8_H                    | 1.00 | 1.00-1.01  | 0.139 |
| CD4CD8_H                 | 0.39 | 0.10-1.56  | 0.183 |
| B_H                      | 1.01 | 0.99-1.02  | 0.377 |
| NK_H                     | 1.00 | 0.99-1.01  | 0.873 |
| Lymphocyte_D             | 0.68 | 0.11-4.28  | 0.685 |
| Neutrophil_D             | 1.73 | 1.10-2.70  | 0.016*|
| NLR_D                    | 1.59 | 1.05-2.41  | 0.030*|
| PLR_D                    | 1.00 | 0.99-1.01  | 0.734 |
| Hemoglobin_D             | 0.98 | 0.93-1.03  | 0.462 |
| PLT_D                    | 0.99 | 0.98-1.01  | 0.415 |
| CRP_D                    | 1.04 | 1.00-1.07  | 0.060 |
| CD3_D                    | 1.00 | 0.99-1.00  | 0.518 |
| CD4_D                    | 1.00 | 0.99-1.00  | 0.610 |
| CD8_D                    | 1.00 | 1.00-1.01  | 0.369 |
| CD4CD8_D                 | 0.180| 0.02-1.37  | 0.099 |
| B_D                      | 0.99 | 0.97-1.01  | 0.386 |
| NK_D                     | 1.00 | 0.99-1.01  | 0.596 |

CI: confidence interval; _H: results at admission; _D: results at discharge; NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; CRP: C-reactive protein; *: P < 0.05.
| Antibody | Status       | 3m     | 6m     | 9m     | 12m    | Number |
|----------|--------------|--------|--------|--------|--------|--------|
| IgG      | Mild/general | Negative| Negative| Missing| Negative| 1      |
|          | Mild/general | Negative| Negative| Negative| Positive| 1      |
|          | Mild/general | Positive| Negative| Missing| Negative| 1      |
|          | Mild/general | Positive| Negative| Missing| Positive| 4      |
|          | Mild/general | Positive| Negative| Positive| Positive| 2      |
|          | Mild/general | Positive| Positive| Missing| Positive| 4      |
|          | Mild/general | Positive| Positive| Negative| Positive| 2      |
|          | Mild/general | Positive| Positive| Negative| Negative| 1      |
|          | Mild/general | Positive| Positive| Positive| Positive| 10     |
|          | Severe/critical | Positive| Negative| Negative| Positive| 1      |
|          | Severe/critical | Positive| Negative| Positive| Negative| 1      |
|          | Severe/critical | Positive| Positive| Missing| Positive| 4      |
|          | Severe/critical | Positive| Positive| Positive| Positive| 2      |
| IgM      | Mild/general | Negative| Negative| Missing| Negative| 8      |
|          | Mild/general | Negative| Negative| Negative| Negative| 11     |
|          | Mild/general | Negative| Negative| Negative| Positive| 2      |
|          | Mild/general | Negative| Negative| Positive| Negative| 2      |
|          | Mild/general | Positive| Negative| Missing| Negative| 1      |
|          | Mild/general | Positive| Positive| Positive| Positive| 2      |
|          | Severe/critical | Negative| Negative| Missing| Negative| 4      |
|          | Severe/critical | Negative| Negative| Negative| Negative| 3      |
|          | Severe/critical | Positive| Negative| Negative| Negative| 1      |